GSK’s Shingrix approved in China for prevention of shingles

GSK (GSK) announced that the China National Medical Products Administration, NMPA, has approved Shingrix for the prevention of shingles in adults aged 18 years and over who are at increased risk of shingles due to immunodeficiency or immunosuppression caused by known disease or therapy. Sanjay Gurunathan, Senior Vice President, Vaccines and Infectious Diseases R&D, said: “This approval marks a critical milestone in expanding access to GSK’s RZV for those at a higher risk of what can be a disrupting and devastating disease. Through close collaboration with regulatory bodies, we continue to drive innovation that helps protect vulnerable patient groups and shifting the focus of healthcare systems towards preventing diseases, like shingles.”